Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross Blue Shield SC specialty drug Prior Aut…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Drug-specific prior authorization criteria for specialty medications

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists coverage criteria, prescriber restrictions, required medical information, coverage durations, and prerequisite therapy rules for specialty and Part D prescription products; it applies to providers requesting benefit coverage or authorization for the listed products.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyDrug-specific prior authorization criteria for specialty medications
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization with indication-specific documentation including diagnosis, required prior therapy trials (TF/C/I), and specialist consultation when specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsMost common coverage duration
    6 monthsInitial coverage common
    ~20Product entries (approx.)
    Prior therapy required (some)Prerequisite therapy
    26218Formulary ID

    Drug-specific Coverage Criteria (Initial and Continuation)

    Drug-specific Coverage Criteria (Initial and Continuation)

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis and indication-specific documentation consistent with the product's labeled and medically-accepted indications (examples below).
    • Oncology & rare disease agents (selected examples)

      • Tumor molecular marker requirement met when specified (e.g., PIK3CA for alpelisib; BRAF V600 for dabrafenib/trametinib combinations; EGFR sensitizing or T790M/other specified EGFR contexts for osimertinib; RET fusion for Retevmo; ROS1 for entrectinib; NTRK fusion for entrectinib/larotrectinib; FGFR2 fusion for Lytgobi).
      • Prior-line therapy and progression requirements met where specified (e.g., prior platinum-based chemotherapy for certain indications; prior anti-angiogenic therapy for lenvatinib combinations; prior systemic therapy for cholangiocarcinoma with FGFR2 fusions).
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyDrug-specific prior authorization criteria for specialty medications
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization with indication-specific documentation including diagnosis, required prior therapy trials (TF/C/I), and specialist consultation when specified.
    SourceLink
    On This Page
    Drug-specific Coverage Criteria (Initial and Continuation)Prior Authorization, Documentation, and Step-Therapy RequirementsFormulary Identifiers, Codes, and Key Clinical ThresholdsKey Clinical Values and Eligibility ThresholdsPolicy Scope and Background NotesKey Definitions and Diagnostic Test Requirements
  1. Appropriate diagnostic testing performed and documented (FDA-cleared or CLIA-certified test results for specified genetic alterations).
  2. Pulmonary & inhaled agents

    • Arformoterol (COPD): Diagnosis of COPD and used for maintenance treatment of bronchoconstriction; authorization for 12 months; subject to Part B vs Part D review.
    • Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex (MAC) lung disease: Diagnosis of MAC lung disease; used as part of combination antibacterial regimen; inadequate sputum culture conversion after ≥6 consecutive months of multidrug background therapy; prescribed by or in consultation with an infectious disease specialist or pulmonologist; 12-month coverage.
    • Bronchitol (inhaled mannitol) for cystic fibrosis: Diagnosis of CF; patient passed Bronchitol Tolerance Test (BTT); prescribed by/with CF care center specialist or pulmonologist; initial 6 months, reauth 12 months with clinical response documented.
  3. Hepatology / metabolic / genetic disorders

    • Cholbam (cholic acid): Bile acid synthesis single enzyme defects — diagnosis confirmed by abnormal urinary bile acid mass spectrometry or molecular genetic testing; peroxisomal disorders — diagnosis plus liver disease or steatorrhea or fat-soluble vitamin deficiency and used adjunctively; initial and reauth durations per product (initial 4 months, reauth 12 months); prescribed by hepatologist, medical geneticist, gastroenterologist, or inborn errors specialist.
    • Cholbam / Gaucher disease notes: where Gaucher-specific criteria apply, confirm diagnosis and any required metabolizer status or testing per product labeling (prescriber specialist involvement as appropriate).
    • Livmarli (maralixibat) for ALGS and Odevixibat for PFIC-related entries: genetic confirmation (JAG1/NOTCH2 for ALGS; ATP8B1/ABCB11/ABCB4/TJP2/NR1H4/MYO5B for PFIC) and trial of prior pruritus treatments; hepatologist/gastroenterologist involvement; coverage durations and reauth response documentation required.
  4. Hematology / complement / thrombocytopenia / PNH

    • Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP): Diagnosis of aTTP; first dose administered as IV bolus by HCP; used with immunosuppressive therapy and plasma exchange or within 59 days after last plasma exchange; prescribed by/with hematologist/oncologist; coverage 3 months.
    • Empaveli (pegcetacoplan) for PNH: Diagnosis of PNH; initial and reauth 12 months; hematologist/oncologist prescriber; reauth requires clinical response documentation.
    • Doptelet (avatrombopag): Indication-specific criteria — thrombocytopenia prior to procedure (baseline platelets <50,000/mcL) or immune thrombocytopenia (baseline <30,000/mcL) with TF/C/I to corticosteroids/IVIG/splenectomy; ITP prescriber restriction to hematologist/oncologist; prerequisite Part D drug may be required per indication.
  5. Autoimmune, rheumatology, dermatology, pulmonary biologics

    • Benlysta (belimumab) for SLE and lupus nephritis: Diagnosis of active SLE with autoantibody positive (ANA ≥1:80 or anti-dsDNA ≥30 IU/mL) and receiving standard-of-care therapy; lupus nephritis requires concomitant standard treatment (e.g., corticosteroids with mycophenolate); Benlysta IV/SC age ≥5 years for specified indications; prescriber restriction to rheumatologist/nephrologist as indicated; initial/reauth 6 months with response documentation.
    • Dupixent (dupilumab): Multiple indication-specific criteria — AD, asthma, CRSwNP, EoE, etc.; age and prescriber restrictions per indication; prior trial/failure of topical/systemic or inhaled therapies as applicable; coverage durations vary by indication (initial 6 months typical; reauth 12 months) and reauth requires demonstrated clinical benefit.
    • Cosentyx (secukinumab), Enbrel (etanercept), Humira, Skyrizi, Stelara, Steqeyma, other biologics: Indication-specific requirements including diagnosis, severity thresholds (e.g., BSA for psoriasis), prior topical/systemic therapy trials, and specialist prescriber or consultation requirements; many rheumatology/dermatology products require trial and failure of conventional therapies and may require demonstration of clinical response for reauthorization.
    • Fasenra, Nucala, Emgality, Aimovig/Qinlock and other CGRP/anti-eosinophil agents: Indication-specific migraine or eosinophilic disease criteria such as minimum migraine days per month, medication-overuse headache considerations, blood eosinophil thresholds, prior therapy trials, age limits, not to be used in combination with another agent in same class for preventive therapy; coverage durations per indication (initial 3–6 months; reauth 12 months).
  6. Immunoglobulin and immune disorders

    • IVIG/SCIG (immune globulin) coverage: Administered at minimum effective dose and frequency for specified diagnoses; initial and reauth criteria list primary immunodeficiencies (CVID, X-linked agammaglobulinemia, SCID, Wiskott-Aldrich, etc.), secondary antibody deficiency (e.g., CLL with Ig <500 mg/dL), neurologic autoimmune disorders (CIDP, GBS, myasthenia gravis) with required prior TF/C/I to steroids/immunosuppressants where indicated; prescriber restriction to specialist with experience in immune globulin therapy; coverage durations 4 months for some transplant uses, 12 months for most diagnoses; documentation of objective improvement required for reauth.
  7. Neurology, movement disorders, SMA, genetic neuromuscular

    • Evrysdi (risdiplam) for SMA: Genetic confirmation of SMN1 mutation or deletion, SMN2 copy number as applicable, baseline motor assessment documentation, not used concomitantly with other chronic SMN-modifying therapies; neurologist with SMA expertise prescriber; initial/reauth 12 months and reauth requires clinical response.
    • Diacomit (stiripentol) for Dravet syndrome: Diagnosis of DS, used with clobazam, weight and age thresholds (≥6 months), neurologist prescriber; 12-month coverage.
    • Inbrija (levodopa inhalation) for Parkinson OFF episodes: Diagnosis of PD with OFF episodes, on carbidopa/levodopa background, TF/C/I to other dopaminergic adjuncts as specified; neurologist prescriber; 12-month coverage.
  8. Hematology / anemia / growth / endocrine

    • Procrit/Retacrit/erythropoiesis-stimulating agents (ESAs): Indication-specific anemia criteria for CKD (Hgb/Hct thresholds), chemotherapy-associated anemia, MDS, preoperative use, hepatitis C-associated anemia with ribavirin, HIV; adequate iron stores required (ferritin >100 mcg/L and TSAT >20%); prescriber restrictions and coverage durations per indication; reauth requires clinical response.
    • Increlex (mecasermin) and other growth hormone-related products: Indications and diagnostic testing for IGF-1 deficiency, severe primary IGF-1 deficiency, GH gene deletion, with endocrinology prescriber and monitoring requirements; 12-month authorizations with response documentation.
  9. Infectious disease, antifungals, antivirals, HCV

    • Pyrimethamine: Authorized only for toxoplasmosis (treatment, secondary prophylaxis, congenital) or primary prophylaxis when TMP-SMX intolerance/desensitization failed or life-threatening reaction to TMP-SMX; prescribed by/with infectious disease specialist; requests for malaria treatment or prophylaxis are excluded (not authorized). Coverage 12 months.
    • Mavyret (glecaprevir/pibrentasvir): Hepatitis C therapy applied consistent with current AASLD/IDSA guidance; not for decompensated liver disease; prescriber restrictions to hepatology/GI/ID or transplant specialists for certain patients; 8–16 week durations per regimen.
    • Itraconazole/posaconazole/other antifungals: Indication-specific prophylaxis or treatment criteria (e.g., HSCT with GVHD, prolonged neutropenia, or resistant OPC), age restrictions, and prescriber expectations; coverage durations per indication.
  10. Rare disease / enzyme / metabolic / genetic specialty agents

    • Lytgobi (futibatinib) for cholangiocarcinoma: FGFR2 fusion/rearrangement confirmed by FDA-cleared or CLIA test; prior systemic therapy required; 12-month coverage.
    • Pyrukynd (mitapivat) for pyruvate kinase deficiency: Molecular confirmation with PKLR variants per labeling, hemoglobin and transfusion dependence criteria, hematologist prescriber; initial and reauth durations per product with response documentation.
    • Skyclarys (for Friedreich's ataxia): Genetic confirmation (FXN mutation) and cardiac biomarker thresholds; neurologist/neurogeneticist prescriber; reauth requires clinical response.
  11. Cardiorenal / lipid / metabolic agents

    • Kerendia (finerenone): CKD with T2D criteria — UACR ≥30 mg/g, eGFR ≥25 mL/min/1.73m2, serum potassium ≤5.0 mEq/L, on maximally tolerated ACE inhibitor or ARB unless contraindicated; cardiologist involvement for HF with LVEF ≥40% as indicated; 12-month auth with response documentation.
    • Repatha / Praluent / Nexletol / Nexlizet: LDL-lowering biologics and oral adjuncts — diagnosis (HeFH, HoFH, ASCVD, primary HLD), LDL thresholds, requirement to continue background lipid-lowering therapy at maximally tolerated doses (or documented intolerance), and reauth requiring LDL reduction evidence.
  12. Pulmonary hypertension and cardiology

    • Ambrisentan, Orenitram, sildenafil for PAH: Diagnosis of symptomatic PAH confirmed by right heart catheterization or current PAH therapy; prescriber pulmonologist or cardiologist; initial and reauth durations with response required.
  13. Other specialty and supportive agents

    • Neulasta (pegfilgrastim) for febrile neutropenia prophylaxis/treatment and ARS: Indication-specific chemotherapy regimen risk thresholds, ARS use, hematology/oncology prescriber; coverage durations per use.
    • Dronabinol for CINV or AIDS anorexia: CINV requires failure/intolerance to listed antiemetics and subject to Part B vs Part D review when used during chemotherapy; AIDS anorexia requires antiretroviral therapy; coverage durations per indication.
  14. Prior Authorization, Documentation, and Step-Therapy Requirements

    Prior Authorization

    Prior Authorization Required — documentation and prescriber specialty

    Prior authorization required for many products in this section. Requests must include indication‑specific documentation (diagnosis, prior therapy trials or contraindications/intolerances, prescriber specialty where required) and objective clinical measures where applicable. Failure to provide required documentation or to meet step‑therapy/prerequisite therapy requirements may result in denial or delay.

    • Ensure prior authorization (PA) request documents the specific diagnosis and meets indication criteria.
    • Include prescriber specialty or documentation of consultation when required (eg, rheumatologist for RA, neurologist for MS, gastroenterologist for IBD, immunologist/allergist for HAE, hepatologist/geneticist for bile acid disorders).
    • Provide objective baseline and follow‑up clinical measures for initial and reauthorization requests (eg, joint counts, BSA for psoriasis, HINE‑2/HFMSE/CHOP‑INTEND for SMA, eosinophil counts for eosinophilic asthma, CRP/ESR/fecal calprotectin for IBD).
    Denial Risk

    Documentation‑linked denials and prohibited combinations

    Denials or requests held for clarification will be issued when documentation does not support the requested indication, requisite prior therapy trials, contraindication/intolerance, or required diagnostic/molecular testing. Provide complete supporting records (clinic notes, lab results, imaging, procedure reports) to avoid documentation‑linked denials.

    • If prerequisite therapy is claimed as failed/intolerant/contraindicated, submit documentation of trial dates, dose, duration (minimum durations where specified), and reason for failure.
    • For reauthorization, document positive clinical response per the indication (examples: reduction in swollen/tender joint count for RA/PJIA, reduction in abscess/inflammatory nodule count for HS, improvement in intestinal inflammation or labs for CD/UC).
    • Missing prerequisite therapy documentation or required baseline measures is a common reason for denial.
    • Requests that seek combination use specifically excluded by policy (eg, MS agents paired with another DMT, use of TTR agents combined with TTR silencers or stabilizers, concomitant chronic SMN‑modifying therapy with Evrysdi) will be denied.
    • Therapies used in disallowed indications (eg, pyrimethamine for malaria) will not be approved.
    Documentation Required

    Onychomycosis and Ciclopirox Nail Lacquer — documentation required

    Onychomycosis (topical ciclopirox and oral antifungals): prior authorization requires confirmation of non‑matrix (lunula) involvement, microbiologic confirmation of fungal infection (KOH, culture, or histology), and documentation of trial and failure/contraindication/intolerance to oral terbinafine for required minimum durations (6 weeks fingernail; 12 weeks toenail) when applicable. For ciclopirox nail lacquer, confirm absence of matrix involvement and provide KOH/culture/histology.

    • Document which nails are affected and severity (target nail description and BSA for skin vs nail involvement).
    • If prescribing topical therapy instead of oral terbinafine, document medical justification (C/I or intolerance) with supporting records.
    • Coverage durations and prerequisite therapy requirements must be met (eg, 48 weeks coverage noted for certain tadalafil products labeled in this block as topical/tabs — ensure correct product indication and formulary match).
    Prior Authorization

    Stelara Induction Dosing Requirement and Reauthorization

    Stelara (ustekinumab) IV induction dosing is required for CD/UC prior to maintenance dosing; induction must follow FDA‑approved weight‑based schedule (260 mg ≤55 kg, 390 mg >55–85 kg, 520 mg >85 kg). Initial requests must indicate induction occurred or be for the IV induction dose; reauthorization requires evidence of clinical response.

    • For infliximab and other IV biologics, include infusion records and weights to verify induction dosing.
    • If induction dosing not documented, request may be denied or held pending verification.
    Step Therapy

    Specialist Prescriber and Prerequisite Therapy — requirements

    Specialist prescriber and prerequisite therapy requirements are enforced for many agents. If policy requires that the drug be prescribed by (or in consultation with) a specific specialist, include a consult note or attestation. Evidence of required step‑therapy or conventional DMARD trial (RA) must be documented with dates, doses, and reasons for failure/intolerance.

    • Rheumatology: RA, PJIA, AS initial requests must be prescribed by or in consultation with a rheumatologist.
    • Dermatology: Psoriasis, HS, and topical/dermatologic biologic starts should be from a dermatologist or with dermatology consult.
    • Gastroenterology: CD and UC initial requests should be from or in consultation with a gastroenterologist.
    • Neurology: MS and SMA agents require neurologist involvement; SMA agents require genetic testing and baseline motor scales.
    • Document conventional DMARD trial for RA at maximally tolerated doses for at least 3 months (methotrexate, leflunomide, or sulfasalazine) unless clearly not appropriate.
    Documentation Required

    Evrysdi — diagnostic and SMA‑specific documentation

    Evrysdi and other SMA therapies: provide genetic confirmation (SMN1 mutation/deletion and SMN2 copy number) and baseline motor function testing appropriate to age (HINE‑2, CHOP‑INTEND, HFMSE, RULM, MFM‑32 or BSID‑III Item 22). Evrysdi is not to be used concomitantly with other chronic SMN‑modifying therapies (eg, nusinersen/Spinraza) and prior gene therapy must be documented with supporting records if applicable.

    • Include genetic test reports showing SMN1 alteration and SMN2 copy number.
    • Attach baseline motor function exam results and any prior SMA‑directed therapy records (including dates and outcomes).
    • Requests indicating concurrent chronic SMN‑modifying therapy will be denied per policy.
    Documentation Required

    HAE Diagnostic Documentation and Prescriber Requirement

    Hem hereditary angioedema (HAE) therapies: diagnosis must be confirmed with appropriate complement testing (low C4 and C1‑INH antigenic or functional deficiency) or, for HAE with normal C1‑INH, documented pathogenic gene variant or family history. Prescriptions should be by or in consultation with an immunologist or allergist. Acute attack treatments are not to be combined with other acute HAE therapies.

    • Provide lab reports for C4 and C1‑INH antigenic/functional levels or genetic testing results.
    • For HAE‑nl‑C1INH, provide genetic testing demonstrating known pathogenic variants (eg, factor XII) or confirmatory family history.
    • State whether request is for on‑demand/acute treatment vs prophylaxis and include prior therapy history.
    Denial Risk

    Pyrimethamine — restricted indications (toxoplasmosis) and malaria prohibition

    Pyrimethamine use is restricted. Approvals are limited to toxoplasmosis (active treatment, secondary prophylaxis, congenital or select primary prophylaxis when TMP‑SMX intolerance or life‑threatening reaction is documented). Pyrimethamine use for malaria treatment or prophylaxis is not authorized and will be denied.

    • For toxoplasmosis, include indication (e.g., encephalitis, ocular, congenital), co‑therapy (eg, sulfadiazine) and prescriber specialty (infectious disease) or consultation note.
    • If used for primary prophylaxis due to TMP‑SMX intolerance, submit documentation of desensitization attempt or prior life‑threatening reaction to TMP‑SMX.
    Documentation Required

    Bile Acid / Peroxisomal Disorder and Livmarli / Cholbam — diagnostic evidence required

    Bile acid synthesis disorders, peroxisomal disorders, Livmarli (maralixibat) and Cholbam: submit disease‑specific diagnostic evidence — abnormal urinary bile acid analysis by mass spectrometry or molecular genetic testing consistent with diagnosis. Peroxisomal disorder requests must document clinical features (eg, liver disease, steatorrhea, fat‑soluble vitamin malabsorption) and that use will be adjunctive. Prescriber should be a hepatologist, geneticist, gastroenterologist, or specialist in inborn errors of metabolism. Initial coverage durations and reauthorization response requirements apply.

    • Attach urinary bile acid analysis results or molecular genetic testing reports.
    • For peroxisomal disorders, document signs/symptoms (liver tests, steatorrhea, growth issues) and planned adjunctive use.
    • Livmarli and similar agents require specialist prescriber attestation and documentation of prior therapies where specified.
    • Initial coverage durations (eg, Cholbam 4 months initial, 12 months reauth) and demonstration of clinical response for reauthorization are required.
    Prior Authorization

    Antivirals, PAH agents, and prophylactic antifungals — required testing and contraindication checks

    Antiviral and hepatic agents (Mavyret, Rebif, Ambrisentan, Posaconazole prophylaxis): PA requires indication confirmation, relevant lab testing, and contraindication/interaction checks. Mavyret requests must not conflict with contraindications listed in policy; missing contraindication‑related documentation may result in denial. Ambrisentan for PAH requires documentation of right‑heart catheterization or other supporting diagnostic evidence and risk‑benefit discussion (hepatotoxicity/pregnancy risk) as appropriate. Posaconazole prophylaxis must meet prophylaxis criteria.

    • For Mavyret, include HCV genotype if relevant and prior HCV treatment history; document any contraindications or drug‑drug interactions.
    • For Rebif and other MS agents, include MS diagnosis and neurologist involvement; combination with another DMT is not allowed.
    • For Ambrisentan, include PAH diagnosis documentation (eg, right heart cath), NYHA class, and pregnancy testing/contraception counseling if applicable.
    • For posaconazole prophylaxis, document high‑risk neutropenia or transplant status per policy criteria.
    Documentation Required

    Armodafinil — diagnostic confirmation required (OSA, narcolepsy)

    Armodafinil and other wakefulness agents: prior authorization requires diagnostic confirmation of the underlying disorder (eg, obstructive sleep apnea with documentation of ongoing excessive daytime sleepiness despite optimized OSA therapy, or narcolepsy diagnosis). Provide sleep study results or documentation of prior therapy trials. Requests lacking diagnostic confirmation will be denied.

    • Attach polysomnography/overnight sleep study reports, multiple sleep latency test (MSLT) when applicable, and documentation of CPAP adherence or reasons CPAP is not effective/appropriate.
    • State the diagnosis clearly (narcolepsy, OSA with residual sleepiness, shift work disorder) and include prior stimulant/modafinil therapy history.
    Documentation Required

    IVIG — dosing, diagnosis, and monitoring documentation

    Intravenous immune globulin (IVIG) and other immunoglobulin therapies: document the minimum effective dose and appropriate frequency, the specific diagnosis meeting policy criteria, prior therapy trials where required, and monitoring labs. Prescriber should have expertise in immunoglobulin management.

    • Include baseline immunoglobulin levels (IgG, IgA) and infection history where indicated.
    • For hematologic/autoimmune indications, document prior corticosteroid and immunosuppressant trials as specified.
    • Provide recent Hct/Hgb and other labs for blood product alternatives (eg, Retacrit requests require Hct/Hgb documentation).
    Prior Authorization

    Molecular Testing and Oncology Prior Authorization

    Molecular testing, tumor‑directed therapy, and oncology agents (eg, Tagrisso, Lumakras, Hyrnuo, Retevmo): include FDA‑approved molecular testing reports (EGFR, KRAS G12C, HER2, RET, ROS1, IDH2, etc.) performed in a CLIA‑certified laboratory, prior lines of therapy, performance status, and relevant imaging or pathology reports. Requests missing molecular confirmation or prior therapy documentation may be denied.

    • Attach the specific test name, result, test date, and lab performing the assay.
    • Document prior systemic therapies and response, and the line of therapy for which the requested agent is being used.
    • For maintenance or continuation approvals, provide prior authorization records or treatment history verifying prior therapy.
    Prior Authorization

    Reauthorization — evidence of clinical response required

    Reauthorization: submit interval clinical outcome data demonstrating benefit (symptom improvement, objective measures, reduced exacerbations/hospitalizations, lab or imaging improvement) and continued specialist management. Lack of documented clinical response may result in non‑renewal.

    • Include comparison to baseline measures submitted at initial approval.
    • For chronic therapies, document adherence and absence of unacceptable toxicity.
    • Reauthorization intervals vary by product (commonly 12 months; some indications have 6‑month initial approvals).
    Step Therapy

    Step‑Therapy / Prerequisite Trials — documentation and enforcement

    Specific pharmacy‑managed exclusions and step therapy enforcement: many medications require documented trial and failure of specified first‑line agents (eg, conventional DMARDs for RA, topical/systemic trials for psoriasis biologics, two trials for Caplyta). If prerequisite therapy was not tried and documented, requests will be denied.

    • Document names, doses, start/end dates, and reason for discontinuation for each prerequisite agent.
    • Where step therapy is enforced (eg, topical or prior systemic trial for psoriasis biologics), include documentation that criteria were met prior to initiating the requested agent.
    Denial Risk

    Prohibited Combination Therapy and Contraindication Checks

    Contraindications and combination exclusions: requests for products used concurrently with explicitly prohibited therapies (eg, Evrysdi with other chronic SMN‑modifying therapies; ATTR‑CM agents used with TTR silencers or stabilizers; MS DMTs in combination) will be denied. For drugs with specific contraindications (eg, Mavyret interactions), include medication reconciliation and interaction checks.

    • State concurrent medications and provide justification if overlapping mechanisms are claimed as necessary.
    • If the request would create a prohibited combination, include clinical rationale and consult notes; absent compelling justification, these requests will be denied.

    Formulary Identifiers, Codes, and Key Clinical Thresholds

    Formulary identifiermixed
    Formulary ID: 26218Document/formulary identifier and version
    No codes listedmixed
    No codes listed
    Formulary Identifiermixed
    Formulary ID: 26218Dupixent and related products (listed under this formulary/version block)
    Products listed (no explicit CPT/HCPCS/ICD-10/NDC codes in excerpt)mixed
    No codes listed
    Codes — not specified in this excerptmixed
    N/ANo explicit CPT/HCPCS/ICD codes provided in this section
    Listed immune globulin productsmixedCovered
    Bivigam INJ 10%, 5GM/50MLProduct listed under IVIG preparations
    PrivigenProduct listed under IVIG preparations
    Policy identifiers referencedmixed
    Formulary ID: 26218Formulary identifier for this policy version
    Listed products (examples)mixed
    RebifProduct listing in policy (Rebif, Rebif Rebidose, Titration packs)
    Referenced comparator therapiesmixed
    AvonexReferenced prior therapy for MS
    BetaseronReferenced prior therapy for MS
    Other listed productsmixed
    NurtecCGRP agent for migraine acute/preventive treatment
    ArmodafinilWakefulness-promoting agent; indications OSA, SWD, narcolepsy
    No specific billing codes listed in this excerptmixed
    No codes listed
    Product strengths/formulations listedmixed
    INJ 2MG/3ML, 4MG/3ML, 8MG/3MLOzempic formulations (as listed)
    Formulary Identifiersmixed
    Formulary ID: 26218Formulary identifier listed for product grouping
    Product listingmixed
    Spevigo INJ 150MG/ML, 300MG/2MLProduct listed — acromegaly criteria referenced (note: Spevigo is a dermatology biologic; listing in document)
    Biologics — Stelara/SteqeymamixedCovered
    Stelara INJ 130MG/26MLT ustekinumab IV induction formulation and dosing for IBD
    Stelara INJ 45MG/0.5ML, 90MG/MLSubcutaneous Stelara maintenance formulations
    Steqeyma INJ 45MG/0.5ML, 90MG/MLIL-23 pathway biologic (product listed with psoriasis/PsA/IBD criteria)
    Steqeyma INJ 130MG/26MLHigher-volume formulation (listed)
    Oncology/rare disease productsmixedCovered
    SucraidSacrosidase for CSID — initial: diagnosis and prescriber restrictions
    Sunitinib MalateSunitinib — RCC, GIST, pNET, adjuvant RCC
    Trientine Hydrochloride CAPS 250MGTrientine — Wilson's disease after penicillamine failure
    VyndamaxTafamidis meglumine (Vyndamax) for ATTR-CM with NYHA I-III
    TafinlarDabrafenib — multiple BRAF V600E/K indications, usually with trametinib
    TagrissoOsimertinib — EGFR-mutated NSCLC criteria
    TalzennaTalazoparib — breast cancer and mCRPC HRR-mutated (combination notes)
    Erlotinib Hydrochloride TABSErlotinib listed (product present)

    Key Clinical Values and Eligibility Thresholds

    inv-162: Migraine attack frequency thresholds (EM/CM)
    Episodic migraine (EM) threshold>= 4 migraine days per month
    Chronic migraine (CM) threshold>= 8 migraine days per month
    Age requirement (initial)18 years or older
    Combination therapy restrictionNot to be used in combination with another CGRP inhibitor for preventive treatment
    inv-163: Alpha-1 antitrypsin level threshold
    Pre-treatment serum AAT threshold< 11 µM/L
    Radial immunodiffusion equivalent< 80 mg/dL
    Nephelometry equivalent< 57 mg/dL
    inv-164: Plaque psoriasis extent threshold (>=3% BSA or severe involvement)
    Plaque psoriasis BSA threshold>= 3% body surface area
    Severe site involvementSevere scalp or palmoplantar/facial/genital involvement qualifies regardless of BSA
    Topical therapy prerequisiteTrial/failure of minimum 30-day topical therapy (14 days for topical corticosteroids) required for initial biologic consideration
    inv-166: Onychomycosis trial durations (fingernail/toenail)
    Fingernail oral terbinafine trialMinimum 6-week trial of oral terbinafine (trial/failure/CI/intolerance) required
    Toenail oral terbinafine trialMinimum 12-week trial of oral terbinafine (trial/failure/CI/intolerance) required
    Microbiologic confirmationOnychomycosis diagnosis must be confirmed by KOH, culture, or histology
    inv-167: HAE prophylaxis age (>=6 years)
    Minimum age for HAE prophylaxis>= 6 years of age
    Diagnostic confirmation requiredLow C4 and C1-INH deficiency/dysfunction or pathogenic mutation/family history for HAE-nl-C1INH
    Prescriber restrictionPrescribed by or in consultation with an immunologist or allergist for prophylaxis
    inv-168: Eosinophil count for Dupixent asthma (>=150 cells/mcL)
    Dupixent asthma eosinophil threshold>= 150 cells/mcL (baseline peripheral blood)
    Exacerbation requirement>=2 exacerbations requiring systemic corticosteroids in past 12 months OR prior asthma-related hospitalization
    Age/prescriber notesAge- and prescriber-specific requirements vary by indication; specialist involvement often required
    inv-169: Deferasirox baseline ferritin (>1,000 mcg/L)
    Baseline ferritin for deferasirox (transfusional)> 1,000 mcg/L
    Transfusion history requirementHistory of transfusion of at least 100 mL/kg packed RBCs for chronic transfusional iron overload
    Coverage duration notesCoverage duration: 12 months for transfusional iron overload; NTDT initial varies
    inv-170: NTDT LIC for deferasirox (>=5 mg Fe/g dw)
    NTDT LIC initial threshold>= 5 mg Fe/g dw (liver iron concentration)
    NTDT serum ferritin alternativeSerum ferritin > 300 mcg/L may support diagnosis
    Age requirement for NTDT initialPatient age >=10 years for NTDT initial
    inv-171: L-glutamine sickle cell crisis frequency (>=2 crises in past 12 months)
    Sickle cell crisis frequency for L-glutamine>= 2 painful crises in the past 12 months
    Indication purposeUse to reduce acute complications of sickle cell disease
    Coverage durationInitial and reauth coverage: 12 months
    inv-172: Peripheral blood eosinophil level (>=150 cells/µL)
    Peripheral blood eosinophil threshold>= 150 cells/µL (baseline) for eosinophilic asthma eligibility
    Alternate historical threshold>= 300 cells/µL within past 12 months may also qualify
    Associated criteriaPlus clinical exacerbation history (eg, >=2 exacerbations) or hospitalization as specified
    inv-173: Baseline prerequisite therapy duration (6 months initial; 12 months reauth where noted)
    Baseline prerequisite therapy duration (initial)6 months prior to initial authorization where specified
    Reauthorization prerequisite12 months required as common reauthorization interval where noted
    ApplicabilityApplies to select immunologic/rheumatologic products requiring prior controller or Part D therapy
    inv-174: Hemoglobin/Hematocrit thresholds for EPO agents (Hct <30% or Hgb <10 g/dL)
    EPO hemoglobin thresholdHgb < 10 g/dL
    EPO hematocrit thresholdHct < 30%
    Iron stores requirementAdequate iron stores required prior to initiation (ferritin >100 mcg/L and TSAT >20%)
    inv-175: Plaque Psoriasis BSA (>=3% or severe involvement)
    Plaque psoriasis BSA threshold (repeat) >= 3% body surface area or severe scalp/palmoplantar/facial/genital involvement
    Topical therapy prerequisiteTrial/failure of minimum 30-day topical therapy (14 days for topical corticosteroids) required before systemic biologic agents
    Prescriber requirementPrescribed by or in consultation with a dermatologist for initial use
    inv-176: Crohn's Disease activity (CDAI >220)
    Crohn's disease activity thresholdCDAI > 220 OR clinical features such as frequent diarrhea/abdominal pain, >=10% weight loss, complications, or abnormal CRP
    Prescriber requirementPrescribed by or in consultation with a gastroenterologist
    Induction dosing noteSome agents require IV induction dosing per product-specific weight-based schedules
    inv-177: IgG level for select secondary antibody deficiency (IgG <500 mg/dL or <400 mg/dL per condition)
    IgG threshold for secondary antibody deficiency (CLL)IgG < 500 mg/dL
    IgG threshold for secondary antibody deficiency (HIV)IgG < 400 mg/dL
    IVIG dosing expectationIVIG administered at the minimum effective dose and appropriate frequency
    inv-178: Height and IGF-1 thresholds for Increlex (Height SDS <= -3.0 and basal IGF-1 SDS <= -3.0)
    Height SDS threshold (Increlex)Height SDS <= -3.0
    Basal IGF-1 SDS thresholdBasal IGF-1 SDS <= -3.0
    Prescriber requirementPrescribed by or in consultation with an endocrinologist
    inv-179: UACR threshold (>=30 mg/g) for Kerendia
    UACR threshold for Kerendia>= 30 mg/g (urine albumin-to-creatinine ratio)
    eGFR requirement>= 25 mL/min/1.73 m2
    Serum potassium requirement<= 5.0 mEq/L prior to initiation
    inv-180: eGFR threshold (>=25 mL/min/1.73 m2) for Kerendia
    eGFR threshold for Kerendia>= 25 mL/min/1.73 m2
    UACR requirement>= 30 mg/g
    Serum potassium requirement<= 5.0 mEq/L prior to initiation
    inv-181: Serum potassium (<=5.0 mEq/L) for Kerendia
    Serum potassium ceiling for Kerendia<= 5.0 mEq/L prior to initiation
    UACR/eGFR co-requirementsUACR >=30 mg/g and eGFR >=25 mL/min/1.73 m2 required
    ACE inhibitor/ARB trialMinimum 30-day trial of maximally tolerated ACE inhibitor or ARB OR documented contraindication/intolerance
    inv-182: Diabetes diagnostic thresholds (A1c >=6.5% OR FPG >=126 mg/dL OR 2-hour OGTT >=200 mg/dL)
    A1c diagnostic thresholdA1c >= 6.5%
    Fasting plasma glucose thresholdFPG >= 126 mg/dL
    2-hour OGTT threshold2-hour OGTT plasma glucose >= 200 mg/dL
    inv-184: Diabetes diagnostic thresholds (A1c >=6.5% OR FPG >=126 mg/dL OR 2-hour OGTT >=200 mg/dL)
    Diabetes diagnostic criteria (repeat)A1c >=6.5% OR FPG >=126 mg/dL OR 2-hour OGTT >=200 mg/dL (acceptable lab evidence)
    Documentation acceptableMedical records/chart notes confirming T2DM may be submitted instead of labs
    Coverage duration noteTypical coverage duration 12 months with reauth requiring clinical response
    inv-184: LDL-C thresholds for Nexletol/Nexlizet (>=55 mg/dL with ASCVD or >=70 mg/dL without ASCVD)
    LDL-C threshold with ASCVD>= 55 mg/dL within last 120 days (with ASCVD)
    LDL-C threshold without ASCVD>= 70 mg/dL within last 120 days (without ASCVD)
    Statin adjunct/intoleranceUsed as adjunct to maximally tolerated statin therapy OR documented statin intolerance/contraindication
    inv-185: HES eosinophil threshold (>=1000 cells/µL)
    HES pre-treatment eosinophil threshold>= 1000 cells/µL
    Duration and exclusionDiagnosis duration >=6 months and secondary causes excluded
    Prior therapy requirementTrial and failure/CI/intolerance to corticosteroid or cytotoxic/immunosuppressive therapy required
    inv-186: Asthma eosinophil thresholds (baseline >=150 cells/µL or >=300 within past 12 months)
    Asthma eosinophil baseline threshold>= 150 cells/µL (baseline) — actionable threshold
    Alternate historical threshold>= 300 cells/µL within past 12 months may be used
    Associated clinical requirementsPlus exacerbation history (eg, >=2 systemic CS exacerbations in past 12 months) or prior hospitalization as specified
    inv-187: Obstructive respiratory events/hour for OSA (>=15 or >=5 with symptoms)
    OSA obstructive events/hour threshold>= 15 obstructive respiratory events per hour on sleep study
    Alternate symptomatic threshold>= 5 events/hour plus associated symptoms (eg, daytime sleepiness, unrefreshing sleep)
    Documentation noteSleep study confirmation required unless prescriber justifies infeasibility
    inv-191: ITP baseline platelet count (<30,000/mcL)
    ITP baseline platelet count threshold< 30,000/mcL
    Prior therapy prerequisiteTrial and failure/intolerance/contraindication to corticosteroids, IVIG, or splenectomy required prior to some therapies
    Prescriber requirementPrescribed by or in consultation with a hematologist/oncologist
    inv-192: Migraine frequency thresholds (EM >=4; CM >=8 days/month)
    Episodic migraine frequency (EM)>= 4 migraine days/month (EM) — actionable
    Chronic migraine frequency (CM)>= 8 migraine days/month (CM)
    Combination therapy exclusionNot used in combination with another CGRP inhibitor for preventive therapy

    Policy Scope and Background Notes

    This policy section lists the product-specific medical necessity requirements for specialty agents used in immunology, rheumatology and related fields. For each listed agent the policy defines required diagnostic confirmation, prescriber restrictions (specialist or consultation when specified), prerequisite therapy trials (trial-and-failure/contraindication/intolerance), and the usual coverage durations (commonly initial 6 months or 12 months for maintenance, with some one‑time induction or shorter initial periods noted). Providers should submit prior authorization requests with the indication-specific documentation, objective disease‑severity measures, and evidence of prior therapy trials exactly as described for each product to support approval or reauthorization.

    Key Definitions and Diagnostic Test Requirements

    b5_0: inv-302: TF/C/I — trial and failure, contraindication, or intolerance
    TF/C/I definitionTrial and failure, contraindication, or intolerance (documented trial and inadequate response or inability to tolerate prior therapy)
    When requiredRequired prior to initiation of many specialty agents (RA, PsO, CD/UC, IBD biologics, some IVIG uses)
    Documentation evidenceMedical records/chart notes reflecting duration and reason (failure/CI/intolerance) should be submitted
    inv-303: FDA-approved or CLIA-approved test — diagnostic assays for genomic alterations
    FDA- or CLIA-approved testing requirementMolecular or genetic alterations must be documented by an FDA-approved or CLIA-certified test (eg, ROS1, NTRK, FGFR2, KRAS, BRAF, RET)
    Tumor marker examplesExamples include FGFR2 fusion/rearrangement for Lytgobi, KRAS G12C for Lumakras, BRAF V600E/K for Mekinist/Tafinlar
    Test sourceAccepts either FDA-cleared assays or tests performed at CLIA-certified laboratories
    inv-304: Autoantibody positive (SLE) — ANA >=1:80 or anti-dsDNA >=30 IU/mL
    Autoantibody positive thresholds (SLE)ANA titer >= 1:80 OR anti-dsDNA >= 30 IU/mL required for Benlysta eligibility
    Concurrent therapyPatient must be receiving at least one standard-of-care treatment for active SLE
    Prescriber requirementPrescribed by or in consultation with a rheumatologist (SLE) or nephrologist for lupus nephritis
    inv-305: HAE diagnostic criteria — low C4 plus C1-INH deficiency or pathogenic mutation
    HAE diagnostic laboratory criteriaLow C4 plus C1-INH antigenic OR functional deficiency (Type I/II) — actionable
    HAE-nl-C1INH pathwayNormal C4/C1-INH with pathogenic mutation detection (eg factor XII, plasminogen) or confirmed family history also qualifies
    Specimen testing standardGenetic testing should be by FDA-approved or CLIA-certified assay where indicated
    inv-306: Onychomycosis confirmation — KOH, culture, or histology required
    Onychomycosis confirmation testsDiagnosis must be confirmed by KOH preparation, culture, or histology
    Matrix involvement exclusionNo lunula (matrix) involvement for topical lacquer eligibility
    Treatment trial requirementTrial/failure/CI/intolerance to oral terbinafine required (6 weeks fingernail, 12 weeks toenail)
    inv-307: Eosinophilic esophagitis (EoE) diagnostic criteria
    EoE diagnostic histology threshold>= 15 intraepithelial eosinophils per high power field
    Symptom requirementSymptoms of esophageal dysfunction (eg dysphagia, food impaction) and exclusion of other causes required
    Prior therapy trialTrial and failure/CI/intolerance to an 8-week PPI or topical esophageal corticosteroid required unless contraindicated
    inv-308: NTDT iron overload definitions for deferasirox
    NTDT iron overload initial definitionLIC >= 5 mg Fe/g dw OR serum ferritin > 300 mcg/L for initial NTDT criteria
    NTDT reauthorization thresholdLIC >= 3 mg Fe/g dw for reauthorization
    Transfusional baseline ferritinBaseline ferritin >1,000 mcg/L required for transfusional iron overload
    inv-309: Positive clinical response — per-product definition at reauthorization
    Positive clinical response requirement at reauthorizationReauthorization generally requires demonstration of positive clinical response per product (eg reduction in swollen/tender joint count, decreased BSA, improved labs)
    DocumentationBaseline and follow-up objective measures should be provided to support continued coverage
    TimingReauth intervals commonly 12 months; initial durations often 6 months
    inv-310: SMA genetic confirmation — SMN1 deletion and SMN2 copy number documentation
    SMA genetic confirmationDetection of SMN1 homozygous deletion or compound heterozygous mutations and documentation of SMN2 copy number (at least 2 copies)
    Baseline motor testingBaseline motor exam scores (HINE-2, HFMSE, CHOP-INTEND, RULM, MFM-32, or BSID-III Item 22) required
    Concomitant therapy exclusionConcomitant chronic SMN-modifying therapy prohibited
    inv-311: HAE diagnostic criteria (repeat) — low C4 plus C1-INH deficiency or functional deficiency or pathogenic mutation
    HAE diagnostic confirmation summaryLow C4 plus C1-INH deficiency/dysfunction OR normal C4/C1-INH with pathogenic mutation or family history
    Tests acceptedC4, antigenic and functional C1-INH assays or FDA/CLIA genetic testing
    PrescriberSpecialist prescriber (immunologist/allergist) commonly required
    inv-314: Minimum effective dose — IVIG administered at minimum effective dose for diagnosis
    IVIG dosing expectationAdministered at the minimum effective dose and appropriate frequency for the diagnosis
    Specialist prescriberPrescriber is or consulted with a physician specialized in immune globulin therapy for initial and reauth
    Required documentationDiagnosis-specific labs (eg IgG levels), prior trials/TF/C/I, and plan for minimum effective dosing must be submitted
    inv-316: UACR definition — urine albumin-to-creatinine ratio required >=30 mg/g for Kerendia
    UACR definition for Kerendia>= 30 mg/g (urine albumin-to-creatinine ratio) — required
    eGFR co-requirement>= 25 mL/min/1.73 m2 also required
    Lab timingLabs should be documented prior to initiation per product guidance
    inv-317: FGFR2 fusion/rearrangement — molecular alteration required for Lytgobi
    FGFR2 fusion/rearrangement requirementFGFR2 fusion or rearrangement detected by FDA-approved or CLIA test required for Lytgobi in intrahepatic cholangiocarcinoma
    Prior therapyPatient must have received prior systemic therapy as specified
    Test standardAccepts FDA-approved assays or CLIA-certified laboratory testing
    inv-318: BRAF V600E/V600K mutant definition for Mekinist/Tafinlar
    BRAF V600E/V600K mutant definitionTumor BRAF V600E or V600K mutation detected by FDA-approved or CLIA test required
    Combination requirementUse often required in combination with partner agent (eg, trametinib/encorafenib) per indication
    Applicable tumor typesMelanoma, NSCLC, ATC, adjuvant melanoma and other solid tumors per product labeling
    inv-319: KRAS G12C mutation — required for Lumakras
    KRAS G12C mutation requirementKRAS G12C mutation detected by FDA-approved or CLIA test required for Lumakras eligibility
    Prior therapyPatient typically must have received at least one prior systemic therapy for NSCLC or prior chemotherapies for mCRC
    Combination note (mCRC)Used in combination with panitumumab for mCRC per product criteria
    inv-320: HeFH / LDL-C thresholds
    LDL-C thresholds (HeFH/ASCVD)LDL-C >=55 mg/dL with ASCVD OR >=70 mg/dL without ASCVD (within last 120 days) — actionable
    Statin adjunct/intoleranceUsed as adjunct to statin therapy or when documented statin intolerance/contraindication exists
    Lab timingLDL-C must be measured within the last 120 days prior to authorization